Demystifying the Results of RTOG 0617: Identification of Dose Sensitive Cardiac Subregions Associated With Overall Survival.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
05 2023
Historique:
received: 05 10 2022
revised: 18 01 2023
accepted: 22 01 2023
medline: 25 4 2023
pubmed: 5 2 2023
entrez: 4 2 2023
Statut: ppublish

Résumé

The RTOG 0617 trial presented a worse survival for patients with lung cancer treated in the high-dose (74 Gy) arm. In multivariable models, radiation level and whole-heart volumetric dose parameters were associated with survival. In this work, we consider heart subregions to explain the observed survival difference between radiation levels. Voxel-based analysis identified anatomical regions where the dose was associated with survival. Bootstrapping clinical and dosimetric variables into an elastic net model selected variables associated with survival. Multivariable Cox regression survival models assessed the significance of dose to the heart subregion, compared with whole heart v5 and v30. Finally, the trial outcome was assessed after propensity score matching of patients on lung dose, heart subregion dose, and tumor volume. A total of 458 patients were eligible for voxel-based analysis. A region of significance (p < 0.001) was identified in the base of the heart. Bootstrapping selected mean lung dose, radiation level, log tumor volume, and heart region dose. The multivariable Cox model exhibited dose to the heart region (p = 0.02), and tumor volume (p = 0.03) were significantly associated with survival, and radiation level was not significant (p = 0.07). The models exhibited that whole heart v5 and v30 were not associated with survival, with radiation level being significant (p < 0.05). In the matched cohort, no significant survival difference was seen between radiation levels. Dose to the base of the heart is associated with overall survival, partly removing the radiation level effect, and explaining that worse survival in the high-dose arm is owing, in part, to the heart subregion dose. By defining a heart avoidance region, future dose escalation trials may be feasible.

Identifiants

pubmed: 36738929
pii: S1556-0864(23)00094-1
doi: 10.1016/j.jtho.2023.01.085
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00533949']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

599-607

Subventions

Organisme : Cancer Research UK
ID : C147/A25254
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C1994/A28701
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 International Association for the Study of Lung Cancer. All rights reserved.

Auteurs

Alan McWilliam (A)

The Division of Cancer Science, The University of Manchester, Manchester, United Kingdom; The Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom. Electronic address: alan.mcwilliam@manchester.ac.uk.

Azadeh Abravan (A)

The Division of Cancer Science, The University of Manchester, Manchester, United Kingdom; The Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom.

Kathryn Banfill (K)

The Division of Cancer Science, The University of Manchester, Manchester, United Kingdom; The Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom.

Corinne Faivre-Finn (C)

The Division of Cancer Science, The University of Manchester, Manchester, United Kingdom; The Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom.

Marcel van Herk (M)

The Division of Cancer Science, The University of Manchester, Manchester, United Kingdom; The Christie National Health Service (NHS) Foundation Trust, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH